Latest Breaking News On - Yingli pharma - Page 1 : comparemela.com

Week In Review: Abbisko Sells China Rights For CSF-1R Inhibitor To Merck In $605M Deal

Week In Review: Abbisko Sells China Rights For CSF-1R Inhibitor To Merck In $605M Deal
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

United statesSouth san franciscoSan diegoNoord hollandHong kongSouth africaInnovent biologicsYingli pharmaAbelzeta pharmaAspen pharmacareCompany newsUniversity of texas md anderson cancer centerAbbisko therapeuticsSan diego shanghaiQuan capitalZeta pharma

FDA clears 280Bio s IND to start Phase I trial of YL-17231

FDA clears 280Bio s IND to start Phase I trial of YL-17231
pharmaceutical-business-review.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceutical-business-review.com Daily Mail and Mail on Sunday newspapers.

University of texasUnited statesZusheng xuYingli pharmaMd anderson cancer centerYingli pharma researchCancer centerPharma research

280 Bio receives IND approval from the FDA for YL-17231

/PRNewswire/ 280Bio, Inc. a clinical stage biotechnology company focused on the development of precision oncology medicines, today announced that the U.S..

United statesZusheng xuYingli pharmaMichael huiMd anderson cancer centerShanghai yingli pharmaceutical co ltdUniversity of texas md anderson cancer centerHead of researchDevelopment of yingli pharmaDrug administrationBio incInvestigational new drugChief executive officerCancer centerGeneral managerSan francisco bay area

Pemigatinib Demonstrates Activity in Previously Treated Solid Tumors Harboring Activating FGFR Alterations

Pemigatinib generated efficacy and tolerability in previously treated patients with advanced/metastatic or unresectable solid tumors harboring activating FGFR mutations or fusions/rearrangements, including cholangiocarcinoma, central nervous system tumors, gynecologic tumors, and pancreatic cancer.

Black diamondUnited statesIsrael generalNuvation bioPemigatinib pemazyreHutchison medipharmaYingli pharmaChinese university of hong kongDepartment of investigational cancer therapeuticsFoundation medicine incUniversity of texas md anderson cancer centerPharma groupSpectrum pharmaceuticalsDebiopharm groupDivision of cancer medicineHebron institute of oncology

280Bio Provides Update on the KRAS Inhibitor TEB-17231 at the 2023 AACR Annual Meeting

280Bio, Inc. a clinical stage biotechnology company, focused on the development of precision oncology medicines, today announced a presentation featuring the Company s lead development

United statesYingli pharmaXu zushengMichael huiHead of researchShanghai yingli pharmaceutical co ltdDevelopment of yingli pharmaMd anderson cancer centerBio incSession categoryCellular biologySession titleRas related signalingMonday aprilPoster boardCancer center